Quantification of Proliferative and Dead Cells in Enteroids
January 31st, 2020
8.2K views
The presented protocol uses flow cytometry to quantify the number of proliferating and dead cells in cultured mouse enteroids. This method is helpful to evaluate the effects of drug treatment on organoid proliferation and survival.
Overview
This protocol outlines a method for isolating enteroids from mouse ileum and assessing cell proliferation and survival using flow cytometry. It is particularly useful for evaluating the effects of drug treatments and inflammatory cytokines on intestinal epithelial cells.
Key Study Components
Area of Science
- Neuroscience
- Cell Biology
- Gastroenterology
Background
- Enteroids are 3D cultures that mimic intestinal epithelium.
- Flow cytometry allows for quantification of cell health and proliferation.
- This technique can be applied to study various treatments affecting intestinal cells.
- It has implications for understanding inflammatory bowel disease.
Purpose of Study
- To isolate intestinal crypts for enteroid culture.
- To investigate the effects of drugs and cytokines on cell survival.
- To enhance understanding of intestinal epithelial dynamics.
Methods Used
- Isolation of intestinal crypts from mouse ileum.
- Culture of enteroids in vitro.
- Application of flow cytometry for cell analysis.
- Assessment of drug effects on cell proliferation and survival.
Main Results
- Successful isolation and culture of enteroids from mouse tissue.
- Quantification of proliferating and dead cells post-treatment.
- Insights into the effects of therapeutic cytokines.
- Potential applications in studying intestinal diseases.
Conclusions
- This method provides a reliable approach to study intestinal epithelial cells.
- It can be adapted for other organoid cultures.
- Future research can explore further therapeutic implications.
Frequently Asked Questions
What are enteroids?
Enteroids are 3D organoid cultures derived from intestinal stem cells that mimic the intestinal epithelium.
How does flow cytometry work in this protocol?
Flow cytometry is used to quantify the number of live and dead cells in the enteroid cultures, providing insights into cell health.
What is the significance of studying drug effects on enteroids?
Studying drug effects helps understand their impact on intestinal cell proliferation and survival, which is crucial for developing treatments for diseases.
Can this method be applied to other tissues?
Yes, while this protocol focuses on intestinal cells, it can be adapted for organoids derived from other tissues.
What are the implications for inflammatory bowel disease?
This technique can help identify therapeutic targets and understand the mechanisms underlying inflammatory bowel disease.
What tools are required for enteroid isolation?
Tissue forceps and iris scissors are recommended for dissecting the ileum from the mouse.
Executive Industry Relevance
Quantitative assessment of proliferative and dead cells in enteroids enables high-confidence evaluation of intestinal epithelial responses to drug candidates and cytokines. This capability supports predictive de-risking at the discovery stage for gastrointestinal disease targets and informs portfolio triage decisions for compounds affecting epithelial barrier integrity. The method's compatibility with flow cytometry ensures scalable, reproducible outputs for cross-program comparison.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables direct quantification of epithelial cell proliferation and death in a controlled, disease-relevant system.
- Supports mechanistic de-risking by distinguishing proliferative from cytotoxic compound effects.
- Facilitates functional target validation for pathways modulating epithelial integrity.
Screening & Assay Development
- Provides a standardized enteroid-based assay platform for compound and cytokine screening.
- Delivers quantitative, reproducible readouts via flow cytometry for high-throughput workflows.
- Enables robust comparison of experimental and control groups for assay optimization.
Translational & Preclinical Research
- Aligns in vitro epithelial responses with translational biomarker strategies for gastrointestinal disease models.
- Supports continuity from early discovery through preclinical validation by quantifying cell fate outcomes.
- De-risks advancement of candidates by linking mechanistic effects to disease-relevant endpoints.
Pipeline & Workflow Integration
This enteroid quantification method integrates into the discovery-to-preclinical continuum, bridging early target validation, compound screening, and translational research for intestinal disease programs.
- Discovery Biology: Enables hypothesis testing on epithelial proliferation and survival under drug or cytokine challenge.
- Screening: Provides assay-ready, reproducible enteroid cultures for compound evaluation.
- Analytics: Generates quantitative flow cytometry data for statistical comparison of treatment effects.
- Translational Research: Connects in vitro epithelial outcomes to preclinical disease models and biomarker development.
- Enterprise Reuse: Adaptable to other organoid systems for broader platform deployment across therapeutic areas.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in epithelial target modulation and compound safety.
- Operational Value: Standardizes enteroid culture and analysis for reproducible, scalable workflows.
- Strategic Value: Informs go/no-go decisions by quantifying both proliferative and cytotoxic responses.
- Portfolio Impact: Supports risk-adjusted prioritization of candidates targeting epithelial barrier function.
Implementation Considerations
- Requires expertise in organoid culture and flow cytometry analysis.
- Demands access to cell dissociation, fixation, and flow cytometry instrumentation.
- Necessitates standardized gating and analysis protocols for cross-study comparability.
- Adaptable to other tissue-derived organoids with protocol optimization.
- Dependent on quality of crypt isolation and enteroid viability for reliable outputs.
Biopharma FAQs
Why does null hypothesis testing matter for EdU and PI quantification?
Null hypothesis testing ensures that observed differences in proliferative or dead cell proportions between treated and control enteroids are statistically significant, supporting robust target validation and compound triage decisions.
How does independent variable isolation fit the enteroid drug screening workflow?
By controlling drug or cytokine exposure in parallel enteroid cultures, the protocol isolates the effect of each variable on epithelial proliferation and death, enabling clear attribution of observed phenotypes to specific interventions.
What do quantitative flow cytometry measurements of EdU and PI enable?
Quantitative flow cytometry provides precise, reproducible counts of proliferative and dead cells, allowing teams to compare treatment effects, optimize dosing, and benchmark candidate performance across studies.
Why are replication requirements critical for cross-functional enteroid studies?
Replicating enteroid assays across multiple wells and experiments ensures data reliability, supports cross-team reproducibility, and enables confident integration of results into broader R&D decision-making pipelines.
What statistical analysis capabilities are required before implementing enteroid quantification?
Teams must establish gating strategies, background subtraction, and statistical comparison methods to interpret flow cytometry data, ensuring that outputs meet enterprise standards for assay validation and portfolio advancement.
